Klas Bergenheim

Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF

Phil McEwan, Oliver Darlington, John J.V. McMurray et al. · European Journal of Heart Failure · 2020 · 155 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)

Phil McEwan, John R. Peters, Klas Bergenheim et al. · Current Medical Research and Opinion · 2005 · 91 citations

Pharmacy, Economics, Pharmacoeconomics +17

Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease

Phil McEwan, Oliver Darlington, Ryan Miller et al. · Clinical Journal of the American Society of Nephrology · 2022 · 64 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +13

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes

P McEwan, Marc Evans, Klas Bergenheim · Diabetes Obesity and Metabolism · 2010 · 53 citations

Pharmacy, Pharmacoeconomics, Cost-effectiveness Analysis +16

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model

Philip McEwan, Thomas Ward, Hayley Bennett et al. · Cost Effectiveness and Resource Allocation · 2015 · 53 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +13